Medicenna Therapeutics Corp (MDNA) - Net Assets

Latest as of September 2025: CA$10.24 Million CAD ≈ $7.41 Million USD

Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) has net assets worth CA$10.24 Million CAD (≈ $7.41 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$18.04 Million ≈ $13.05 Million USD) and total liabilities (CA$7.80 Million ≈ $5.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MDNA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$10.24 Million
% of Total Assets	56.77%
Annual Growth Rate	N/A
5-Year Change	-49.94%
10-Year Change	750.6%
Growth Volatility	405.14

Medicenna Therapeutics Corp - Net Assets Trend (2014–2025)

This chart illustrates how Medicenna Therapeutics Corp's net assets have evolved over time, based on quarterly financial data. Also explore MDNA current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Medicenna Therapeutics Corp (2014–2025)

The table below shows the annual net assets of Medicenna Therapeutics Corp from 2014 to 2025. For live valuation and market cap data, see Medicenna Therapeutics Corp (MDNA) market capitalisation.

Year	Net Assets	Change
2025-03-31	CA$19.09 Million ≈ $13.81 Million	+267.85%
2024-03-31	CA$5.19 Million ≈ $3.76 Million	-82.40%
2023-03-31	CA$29.49 Million ≈ $21.33 Million	+41.52%
2022-03-31	CA$20.84 Million ≈ $15.07 Million	-45.38%
2021-03-31	CA$38.15 Million ≈ $27.59 Million	+5.52%
2020-03-31	CA$36.15 Million ≈ $26.15 Million	+1281.55%
2019-03-31	CA$2.62 Million ≈ $1.89 Million	+21.03%
2018-03-31	CA$2.16 Million ≈ $1.56 Million	-67.52%
2017-03-31	CA$6.66 Million ≈ $4.82 Million	+196.53%
2016-03-31	CA$2.24 Million ≈ $1.62 Million	+11729.16%
2015-03-31	CA$-19.30K ≈ $-13.96K	+92.77%
2014-03-31	CA$-267.05K ≈ $-193.18K	--

Equity Component Analysis

This analysis shows how different components contribute to Medicenna Therapeutics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11743465500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Common Stock	CA$116.30 Million	609.04%
Other Comprehensive Income	CA$3.00K	0.02%
Other Components	CA$21.05 Million	110.22%
Total Equity	CA$19.09 Million	100.00%

Medicenna Therapeutics Corp Competitors by Market Cap

The table below lists competitors of Medicenna Therapeutics Corp ranked by their market capitalization.

Company	Market Cap
Drax Group PLC LSE:DRX	$36.82 Million
Hidropar Hareket Kontrol Teknolojileri Merkezi Sanayi ve Ticaret A.S. IS:HKTM	$36.83 Million
Xiabuxiabu Catering Management (China) Holdings Co. Ltd F:0XI	$36.86 Million
Xilio Development Inc NASDAQ:XLO	$36.86 Million
Environmental Clean Technologies Ltd AU:ECT	$36.80 Million
Harn Engineering Solutions Public Company Limited BK:HARN	$36.80 Million
Advance Zinctek Ltd AU:ANO	$36.79 Million
Inzi Display Co.Ltd KQ:037330	$36.78 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medicenna Therapeutics Corp's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 5,191,000 to 19,095,000, a change of 13,904,000 (267.8%).
Net loss of 11,805,000 reduced equity.
Share repurchases of 23,511,000 reduced equity.
New share issuances of 19,714,000 increased equity.
Other comprehensive income decreased equity by 16,000.
Other factors increased equity by 29,522,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CA$-11.80 Million	-61.82%
Share Repurchases	CA$23.51 Million	-123.13%
Share Issuances	CA$19.71 Million	+103.24%
Other Comprehensive Income	CA$-16.00K	-0.08%
Other Changes	CA$29.52 Million	+154.61%
Total Change	CA$-	267.85%

Book Value vs Market Value Analysis

This analysis compares Medicenna Therapeutics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.45x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-03-31	CA$-0.02	CA$0.61	x
2015-03-31	CA$0.00	CA$0.61	x
2016-03-31	CA$0.14	CA$0.61	x
2017-03-31	CA$0.39	CA$0.61	x
2018-03-31	CA$0.09	CA$0.61	x
2019-03-31	CA$0.10	CA$0.61	x
2020-03-31	CA$1.13	CA$0.61	x
2021-03-31	CA$0.77	CA$0.61	x
2022-03-31	CA$0.38	CA$0.61	x
2023-03-31	CA$0.46	CA$0.61	x
2024-03-31	CA$0.07	CA$0.61	x
2025-03-31	CA$0.25	CA$0.61	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medicenna Therapeutics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -61.82%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.49x
Recent ROE (-61.82%) is above the historical average (-118.60%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	0.00%	0.00%	0.00x	0.00x	CA$-739.07K
2015	0.00%	0.00%	0.00x	0.00x	CA$-831.56K
2016	-59.43%	0.00%	0.00x	2.56x	CA$-1.56 Million
2017	-114.64%	0.00%	0.00x	2.18x	CA$-8.30 Million
2018	-345.33%	0.00%	0.00x	2.02x	CA$-7.68 Million
2019	-179.93%	0.00%	0.00x	1.98x	CA$-4.97 Million
2020	-22.99%	0.00%	0.00x	1.05x	CA$-11.92 Million
2021	-45.05%	0.00%	0.00x	1.11x	CA$-21.00 Million
2022	-108.69%	0.00%	0.00x	1.13x	CA$-24.73 Million
2023	5.25%	0.00%	0.00x	1.24x	CA$-1.40 Million
2024	-490.58%	0.00%	0.00x	3.69x	CA$-25.99 Million
2025	-61.82%	0.00%	0.00x	1.49x	CA$-13.71 Million

Industry Comparison

This section compares Medicenna Therapeutics Corp's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $24,209,535
Average return on equity (ROE) among peers: -379.23%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medicenna Therapeutics Corp (MDNA)	CA$10.24 Million	0.00%	0.76x	$36.81 Million
Appili Therapeutics Inc (APLI)	$-13.40 Million	0.00%	0.00x	$1.86 Million
Aptose Biosciences Inc (APS)	$7.33 Million	-189.11%	0.18x	$4.36 Million
Arch Biopartners Inc (ARCH)	$1.06 Million	-79.15%	0.19x	$20.88 Million
Biomind Labs Inc (BMND)	$-1.30 Million	0.00%	0.00x	$6.98 Million
Cybin Inc (CYBN)	$237.20 Million	-47.70%	0.09x	$301.37 Million
Eupraxia Pharmaceuticals Inc (EPRX)	$1.18 Million	-3177.89%	21.71x	$393.86 Million
Devonian Health Group Inc (GSD)	$14.25 Million	-32.28%	0.35x	$20.01 Million
Helix BioPharma Corp. (HBP)	$-1.39 Million	0.00%	0.00x	$116.58 Million
Hemostemix Inc (HEM)	$-6.77 Million	0.00%	0.00x	$8.18 Million
Universal Ibogaine Inc (IBO)	$3.94 Million	-266.20%	0.60x	$1.13 Million

About Medicenna Therapeutics Corp

TO:MDNA Canada Biotechnology

Market Cap

$36.81 Million

CA$50.88 Million CAD

Market Cap Rank

#22994 Global

#843 in Canada

Share Price

CA$0.61

Change (1 day)

+3.39%

52-Week Range

CA$0.57 - CA$1.64

All Time High

CA$7.00